Recombinant Human NHEJ1 Protein, N-His from ProteoGenix; catalogue ARO-P12118; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant proteins have become essential tools in the fields of biotechnology and medicine. They are produced by genetically engineering organisms to express specific proteins that have therapeutic, diagnostic, or research applications. One such protein is the Recombinant Human NHEJ1 Protein, which plays a crucial role in DNA repair and has potential applications in cancer treatment and gene therapy. In this article, we will delve into the structure, activity, and applications of this important recombinant protein.
The Recombinant Human NHEJ1 Protein is a 39 kDa protein that consists of 354 amino acids. It is encoded by the NHEJ1 gene, also known as Cernunnos, and is highly conserved among different species. The protein is composed of two domains, the N-terminal domain and the C-terminal domain, connected by a flexible linker region.
The N-terminal domain contains a BRCT (BRCA1 C-terminus) motif, which is involved in protein-protein interactions and is essential for the recruitment of NHEJ1 to DNA damage sites. The C-terminal domain contains a SAP (SAF-A/B, Acinus, and PIAS) motif, which is responsible for binding to DNA and is crucial for the protein’s activity in DNA repair.
The main function of Recombinant Human NHEJ1 Protein is to repair DNA double-strand breaks (DSBs), which are the most dangerous type of DNA damage. DSBs can be caused by various factors, including radiation, chemicals, and errors during DNA replication. If left unrepaired, DSBs can lead to cell death or genomic instability, which can contribute to the development of diseases such as cancer.
NHEJ1 is a key component of the non-homologous end joining (NHEJ) pathway, which is the primary mechanism for repairing DSBs in mammalian cells. NHEJ1 works by binding to the broken DNA ends and recruiting other proteins to form a complex that repairs the damage. It also plays a crucial role in regulating the activity of other NHEJ proteins, ensuring efficient and accurate repair of DSBs.
The role of NHEJ1 in DNA repair makes it a promising target for cancer treatment and gene therapy. Cancer cells often have defects in the NHEJ pathway, making them more reliant on other DNA repair mechanisms. By inhibiting NHEJ1, it is possible to selectively kill cancer cells while sparing healthy cells that have intact NHEJ function.
Moreover, NHEJ1 has been shown to enhance the efficiency of gene therapy, which involves introducing new genetic material into cells to treat genetic disorders. By co-delivering NHEJ1 with the therapeutic gene, it is possible to increase the integration of the gene into the cell’s genome, leading to more effective treatment.
The Recombinant Human NHEJ1 Protein is a vital component of the NHEJ pathway, responsible for repairing DNA double-strand breaks. Its structure, activity, and applications make it a valuable tool in cancer treatment and gene therapy. Further research on this protein could lead to the development of novel therapies for various diseases.
ProteoGenix catalogue number ARO-P12118. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 16.53 kDa; Fragment: Met1-Ser127; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
